Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

June 27, 2008 09:00 ET

Ambrilia Announces Executive Departure

MONTREAL, QUEBEC--(Marketwire - June 27, 2008) - Ambrilia Biopharma Inc. (TSX:AMB) today announced the departure of Dr. Jinzi Wu as Vice-President, Preclinical and Basic Research, effective immediately. Dr. Wu is leaving the Company to join a major pharmaceutical company in the U.S.

Until the end of 2008, the preclinical and basic research team will report directly to Dr. Bonabes de Rouge, Senior Executive Vice-President and CSO.

"On behalf of all of us at Ambrilia, I wish to thank Jinzi for his contribution in building the Company's expertise in antivirals and wish him the best of luck in his new undertaking," said Dr. Philippe Calais, President and CEO. "By the same token, I want to reiterate that we have a strong and talented preclinical and research team, based in the Montreal and Marseille sites, entirely dedicated to the antivirals product portfolio. This departure does not diminish in anyway Ambrilia's commitment and recent steps forward in the strategy execution".

Ambrilia's strategy is to capitalize on its broad product portfolio and original expertise in virology. During the course of 2008, execution of the strategy aims to monetize the non-virology assets through third parties agreements, in turn strengthening the Company's financial position to continue building its novel pipeline of antivirals.


This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. There is a risk that expectations and forward looking statements will not prove to be accurate. Readers are cautioned not to place undue reliance on these forward-looking statements as they involve risks and uncertainties, which could make actual results differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. We refer you to the Risk Factors section of the Company's annual information form which contains a more exhaustive analysis of the risks and uncertainties that are generally connected to the business of the Company. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements, unless obligated to do so by applicable securities laws.


Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, a HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, HCV entry and polymerase inhibitors and Anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

Contact Information